Trial Profile

An Open Label, Phase Ib/II Trial to Study the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With Toripalimab in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavorixafor (Primary) ; Toripalimab (Primary)
Indications Advanced breast cancer; Breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Abbisko Therapeutics

05 Nov 2020 According to a X4 Pharmaceuticals media release, data anticipated in first half 2021.
15 Oct 2020 New trial record
09 Sep 2020 According to an Abbisko Therapeutics media release, the company received Investigational New Drug Application approval to initiate this trial in China.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com